- Approval Id
- 814bc3d9bf574097
- Drug Name
- Cubicin (daptomycin for injection) 500mg
- Product Name
- Cubicin (daptomycin for injection) 500mg
- Approval Number
- SIN13501P
- Approval Date
- 2008-07-28
- Registrant
- MSD PHARMA (SINGAPORE) PTE. LTD.
- Licence Holder
- MSD PHARMA (SINGAPORE) PTE. LTD.
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Dosage
- **2\. DOSAGE AND ADMINISTRATION**
**2.1 General**
CUBICIN is given by intravenous (IV) administration.
CUBICIN is a sterile product contained in a single-dose vial.
**2.2 Adults**
**Complicated Skin and Skin Structure Infections**
CUBICIN 4 mg/kg is administered to adult patients intravenously in 0.9% sodium chloride for injection once every 24 hours for 7 to 14 days, either by injection over a 2-minute period or by infusion over a 30-minute period. Do not dose CUBICIN more frequently than once a day, and measure creatine phosphokinase (CPK) levels at baseline and at regular intervals (at least weekly). _\[See 3 INSTRUCTIONS FOR USE, 3.1 Preparation of CUBICIN for Administration_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. _\]_
**_Staphylococcus aureus_ Bloodstream Infections (Bacteremia)**
CUBICIN 6 mg/kg is administered to adult patients intravenously in 0.9% sodium chloride for injection once every 24 hours for 2 to 6 weeks, either by injection over a 2-minute period or by infusion over a 30-minute period. Duration of treatment is based on the treating physician’s working diagnosis. Do not dose CUBICIN more frequently than once a day, and measure CPK levels at baseline and at regular intervals (at least weekly). _\[See 3 INSTRUCTIONS FOR USE, 3.1 Preparation of CUBICIN for Administration_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. _\]_
**2.3 Pediatric Patients (1 to 17 Years of Age)**
**Complicated Skin and Skin Structure Infections**
The recommended dosage regimens based on age for pediatric patients with cSSSI are shown in Table 1. CUBICIN should be administered intravenously in 0.9% sodium chloride for injection once every 24 hours for up to 14 days.
**Unlike in adults, CUBICIN should not be administered by injection over a two (2) minute period in pediatric patients.**
**_Staphylococcus aureus_ Bloodstream Infections (Bacteremia)**
The recommended dosage regimens based on age for pediatric patients with _S. aureus_ bloodstream infections (bacteremia) are shown in Table 2. CUBICIN should be administered intravenously in 0.9% sodium chloride for injection once every 24 hours for up to 42 days.
**2.4 Renal Impairment**
Daptomycin is eliminated primarily by the kidneys; therefore, an adjustment of CUBICIN dosage interval is recommended for adult patients with creatinine clearance (CLCR) <30 mL/min, including patients receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The recommended dosing regimen for these adult patients is 4 mg/kg (cSSSI) or 6 mg/kg ( _S. aureus_ bloodstream infections) once every 48 hours. When possible, administer CUBICIN following the completion of hemodialysis on hemodialysis days. In adult patients with renal impairment, monitor both renal function and CPK more frequently than once weekly.
No dosage interval adjustment is required for adult patients with CLCR ≥30 mL/min.
Due to limited clinical experience, CUBICIN should only be used in adult patients with any degree of renal impairment (creatinine clearance <80 mL/min) when it is considered that the expected clinical benefit outweighs the potential risk. The response to treatment and renal function should be closely monitored in all adult patients with some degree of renal impairment.
Dose adjustments in adult patients with renal impairment by indication and creatinine clearance:
The dosage regimen for CUBICIN in pediatric patients with renal impairment has not been established.
- Route Of Administration
- INTRAVENOUS
- Indication Info
- **1\. INDICATIONS AND USAGE**
CUBICIN is indicated for the treatment of the infections listed below.
**1.1 Complicated Skin and Skin Structure Infections**
Adult (≥18 years of age) and pediatric (1 to 17 years of age) patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: _Staphylococcus aureus_ (including methicillin-resistant isolates), _Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae_ subsp. _equisimilis,_ and _Enterococcus faecalis_ (vancomycin-susceptible isolates only).
**1.2 _Staphylococcus aureus_ Bloodstream Infections (Bacteremia)**
Adult patients (≥18 years of age) with _Staphylococcus aureus_ bloodstream infections (bacteremia), including those with right-sided infective endocarditis (SAB/RIE), caused by methicillin-susceptible and methicillin-resistant isolates.
Pediatric patients (1 to 17 years of age) with _S. aureus_ bloodstream infections (bacteremia) caused by methicillin-susceptible and methicillin-resistant isolates.
CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to _S. aureus_. The efficacy of CUBICIN in patients with left-sided infective endocarditis due to _S. aureus_ has not been demonstrated. The clinical trial of CUBICIN in patients with _S. aureus_ bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor. CUBICIN has not been studied in patients with prosthetic valve endocarditis.
CUBICIN is not indicated for the treatment of pneumonia _\[See 5 WARNINGS AND PRECAUTIONS, 5.2 Pneumonia_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
- Contraindications
- **4\. CONTRAINDICATIONS**
CUBICIN is contraindicated in patients with known hypersensitivity to daptomycin.
- Pharma Manufacturer Name
- MSD PHARMA (SINGAPORE) PTE. LTD.
- Company Detail Path
- /organization/msd-pharma-singapore-pte-ltd
